Archive — US — techcrunch
H1 secures $40M from CVS, proving SaaS startups can still attract investment
H1, a healthcare data platform, secured $40M from CVS Health Ventures, highlighting the resilience of SaaS startups amidst heightened investment in AI. CEO Ariel Katz argues that the value of H1's data on doctors makes it less vulnerable to AI competition. Despite current VC trends favoring AI, H1's strong profitability and growth prospects remain attractive for investors.
Key points
- H1 secured a $40 million investment from CVS Health Ventures.
- CEO Ariel Katz argues that not all SaaS companies are suffering; those with unique data offerings can still attract investment.
- H1 is profitable and forecast 40% growth this year, highlighting its strong financial health.
- Traditional VCs are currently favoring AI startups, making funding challenges for non-AI SaaS companies.
- H1's last valuation was $750 million in November 2021, prior to market downturns.
Why it matters
- The rise of AI has caused a 'SaaSocalypse' for some startups, but H1's data-centric model stands in contrast.
- The funding dynamics reflect larger trends in the tech investment landscape, particularly the shift towards AI and automation.
- H1's focus on acquisitions for growth mirrors strategies in an evolving post-COVID market aiming for profitability.
H1's successful fundraising amidst an AI-focused venture capital climate demonstrates that unique data-driven SaaS models can still attract funding, signifying a potential shift back to valuing essential healthcare data in startup investments.